Alzheimer’s disease is the most common cause of dementia, slowly damaging memory, thinking and daily function as brain cells are lost. Because the disease involves inflammation and widespread cell loss, researchers are exploring whether stem cells, mostly mesenchymal stromal cells, could reduce inflammation or support brain cells.
AT A GLANCE · ALZHEIMER’S DISEASE
| Evidence level | Early research |
|---|---|
| Approved stem cell treatment? | No stem cell therapy is approved for Alzheimer’s disease or any other dementia by the US FDA, the European EMA or regulators in Japan or Korea. |
| Typical private price | $5,000 – $30,000 (indicative) |
| Recruiting trials | 13 listed on ClinicalTrials.gov (4 October 2026) |
| Last reviewed | October 2026 |
Does stem cell therapy work for Alzheimer’s disease?
Much of the encouraging work is in mice and lab models, which often fail to translate to people. Human studies are small and early-phase. A US phase 1 trial (Alzheimer’s & Dementia, 2022) gave donor mesenchymal cells by IV to 33 people with mild Alzheimer’s and mainly showed acceptable safety.
A follow-up randomised, double-blind phase 2a trial in 49 people with mild Alzheimer’s (Nature Medicine, 2025) met its safety goal and reported less brain shrinkage and some better cognitive test scores than placebo, but the authors stress it was small and short and that larger trials are needed. Small studies in South Korea that injected cells into the brain’s fluid spaces have also focused on safety. No trial has yet shown that stem cells slow, stop or reverse Alzheimer’s in a way that matters for daily life.
Is any stem cell treatment approved for Alzheimer’s disease?
No stem cell therapy is approved for Alzheimer’s disease or any other dementia by the US FDA, the European EMA or regulators in Japan or Korea. Stem cell treatment for dementia is available legitimately only in registered clinical trials.
What private clinics offer — and how it compares
Clinics sell IV or nasal ‘stem cell’ or exosome treatments for memory loss and dementia, sometimes promising improved memory or a halt to decline. These claims go far beyond small early-phase trials, which were designed mainly to check safety.
Proven treatments to discuss first
Before paying for an experimental option, make sure you have explored the established treatments for Alzheimer’s disease with your doctor:
- Thorough diagnosis by a memory clinic or specialist, including treatable causes of memory problems
- Cholinesterase inhibitors and memantine to help with symptoms
- Anti-amyloid antibody treatments for eligible people with early Alzheimer’s, where approved
- Managing blood pressure, diabetes, hearing loss and other risk factors
- Physical activity, social engagement and cognitive stimulation
- Support and planning for carers, plus help with sleep, mood and behaviour changes
How much does stem cell therapy for Alzheimer’s disease cost?
Private clinics typically quote $5,000 to $30,000. There is little systematic reporting of dementia-specific clinic prices; general reporting on unapproved stem cell clinics describes charges from several thousand to tens of thousands of dollars per course. These figures are approximate. Compare prices by country in our cost guide and location guides, and check insurance coverage.
Risks and side effects
- Infusion reactions, fever and infection
- Blood clots from cells given into the bloodstream
- Contamination or unknown contents in unregulated products, including exosome products
- Consent concerns when a person with dementia cannot fully weigh risks and costs
- Financial harm and stress for families, and delay of proven care or trials
Recruiting clinical trials for alzheimer’s disease
On 4 October 2026, ClinicalTrials.gov listed 13 recruiting or soon-to-recruit stem cell studies for this condition, 6 with sites in the United States. Here are up to eight, latest-stage first:
| Study | Phase | Locations | Status |
|---|---|---|---|
| Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer’s Disease. | Phase 2 | United States | Recruiting |
| Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer’s Disease. | Phase 2 | United States | Recruiting |
| Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease | Phase 1/Phase 2 | France | Recruiting |
| The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer’s Disease | Phase 1/Phase 2 | China | Recruiting |
| Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions | Phase 1/Phase 2 | United States | Recruiting |
| Stem Cell Therapy for Early Alzheimer’s Disease | Phase 1/Phase 2 | United States | Recruiting |
| Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases | N/A | Israel | Recruiting |
| Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer’s Disease | Early Phase 1 | China | Recruiting |
See all matching studies on ClinicalTrials.gov. A listing is not an endorsement: registration does not mean a study is safe or effective, and genuine trials rarely charge you for the experimental treatment. Ask the study team about costs, placebo groups and follow-up before you enrol. See our clinical trials hub.
Questions to ask before you agree to treatment
- Which human trials support this treatment for Alzheimer’s, and were they placebo-controlled?
- How will you assess capacity and consent, and involve family or carers in decisions?
- What exactly is being given, how is it made and tested, and what side effects have you seen?
- Could this treatment exclude my relative from approved therapies or legitimate clinical trials?
Before You Pay: The Stem Cell Clinic Checklist
- 20 questions every legitimate clinic should answer in writing
- A red-flag scorecard to spot unregulated marketing
- Realistic 2026 cost ranges: US, Mexico, Panama & Europe
- How to find a registered clinical trial
Red flags to watch for
- Claims to reverse memory loss or ‘cure’ dementia
- Pressure on family members to decide quickly or pay upfront
- Treatment offered without a proper diagnosis or memory assessment
Stem cell therapy for Alzheimer’s disease: FAQs
Does stem cell therapy work for Alzheimer’s?
It has not been proven to. Small early trials suggest donor mesenchymal cells appear reasonably safe and a 2025 phase 2a trial reported some promising signals, but it involved only 49 people. Larger trials are needed before anyone can say it works.
Is stem cell therapy FDA approved for Alzheimer’s or dementia?
No. No stem cell or exosome product is FDA-approved for any form of dementia. Approved options include symptom medicines and, for some people with early Alzheimer’s, anti-amyloid antibody treatments.
How much does stem cell therapy for dementia cost?
Private clinics typically charge several thousand to tens of thousands of dollars per course, and insurance does not cover it. Joining a registered clinical trial is usually free.
Can stem cells reverse memory loss?
There is no good evidence that stem cells reverse memory loss in people. Results in mice have not yet been confirmed in well-controlled human trials.
Is stem cell therapy for Alzheimer’s covered by insurance?
No, because it is unapproved and experimental. Memory clinic assessments, approved medicines and some support services are more likely to be covered.
Related guides
- Stem cell therapy for autism
- Stem cell therapy for spinal cord injury
- Stem cell therapy for multiple sclerosis
- Stem cell therapy for ALS
- All conditions · Types of stem cell treatment · Clinical trials hub
Sources
- Allogeneic mesenchymal stem cell therapy in mild Alzheimer’s disease: a randomized controlled phase 2a trial (Nature Medicine, 2025)
- Results and insights from a phase I clinical trial of mesenchymal cells for Alzheimer’s disease (Alzheimer’s & Dementia, 2022)
- Therapeutic efficacy of mesenchymal stem cells on Alzheimer’s disease: review of clinical results (PubMed)
- Advances in stem cell therapy in Alzheimer’s disease: a comprehensive clinical trial review (Stem Cell Investigation)
- Researchers find success with stem cell therapy in mouse model of Alzheimer’s disease (Stanford Medicine, 2023)
- FDA: Consumer alert on regenerative medicine products including stem cells and exosomes
Last reviewed October 2026. For general information only — not medical advice. We do not endorse any clinic or product. Always consult a qualified, licensed healthcare professional. See our medical disclaimer and editorial policy.